Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10541 in KRAS G12C Mutation Advanced Solid Tumors
NCT07615413Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Jun 2026
- Primary completion
- Jun 2029
01
Overview
Phase 1, open-label trial of HS-10541 in solid tumor, sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity at 21 days, Adverse events at 1.5 years and 2 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
HS-10541
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07615413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615413.